Galectin Therapeutics Inc. (GALT)
NASDAQ: GALTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
GALT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $271.35M
- EPS (TTM)
- -$0.32
- Dividend yield
- None
- 52-week range
- 2.03 – 7.13
- Day range
- 2.67 – 2.93
- Volume / Avg
- 257.65K / 252.31K
- Beta
- —
- Shares outstanding
- 100.88M
52-week range
GALT stock today
Shares of Galectin Therapeutics (GALT) finished lower on Nov 20 at $2.69, a drop of 4.27% or $0.12 per share, versus the S&P 500's 3.70% decline. At this level, GALT sits near the bottom of its 52-week range of $2.03 to $7.13: 62.3% below the high, set on Dec 17, 2025 and 32.5% above the low. GALT is down 35.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 49.7%.
Galectin Therapeutics has posted a net loss over the last twelve months (EPS of -$0.32), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Galectin Therapeutics
Company profileGalectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Joel Lewis CPA
- Headquarters
- Norcross, GA
- Employees
- 9
- Website
- galectintherapeutics.com
Financial highlights
Full financialsGalectin Therapeutics reported a net loss of $30.8 million, compared with a loss of $47.0 million a year earlier. Diluted earnings per share came in at -$0.48.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-30.84M | $-47.05M | $-41.07M | $-38.78M | $-30.53M |
| EPS (diluted) | $-0.48 | $-0.76 | $-0.74 | $-0.65 | $-0.52 |
Analyst forecast
ForecastConsensus (1 analysts)
strong_buy
Avg. price target
$11.00+308.92%
- Strong buy 0
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 16, 2026
- EPS actual vs est.
- $-0.04 vs $-0.05
- Surprise
- +20.00%
GALT news
All GALT newsGalectin Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| VCREVicore Pharma Holding AB ADR | 9.41 | -5.09% | $264.89M | vs GALT |
| RLMDRelmada Therapeutics Inc. | 2.62 | -15.76% | $279.54M | vs GALT |
| FULCFulcrum Therapeutics Inc. | 3.69 | -0.54% | $281.85M | vs GALT |
| GLSIGreenwich LifeSciences Inc. | 19.25 | -2.73% | $282.56M | vs GALT |
| EBSEmergent BioSolutions Inc. | 5.05 | -1.94% | $259.65M | vs GALT |
| ALTAltimmune Inc. | 1.33 | -5.67% | $258.80M | vs GALT |
| PRLDPrelude Therapeutics Incorporated | 3.23 | -0.77% | $258.63M | vs GALT |
| BNTCBenitec Biopharma Inc. | 7.92 | -2.76% | $285.88M | vs GALT |
Indexes, lists and sector
Galectin Therapeutics stock FAQ
What is Galectin Therapeutics's stock price today?
GALT last traded at $2.69 as of Nov 20, 4:00 PM EST, down 4.27% on the day. Prices are delayed at least 15 minutes.
Does Galectin Therapeutics pay a dividend?
No. Galectin Therapeutics does not currently pay a regular cash dividend.
Who is Galectin Therapeutics's CEO?
Mr. Joel Lewis CPA is the chief executive officer of Galectin Therapeutics Inc., which has about 9 employees.
Has GALT ever split its stock?
Yes. The most recent GALT stock split was a 1-for-6 split on Mar 23, 2012.
What is the GALT 52-week high?
The 52-week high for GALT is $7.13 and the 52-week low is $2.03. The stock is currently 62.3% below its high.